肺癌患者TXB2、PAgT、6-Keto-PGF1α的临床意义

摘要

Objective　To explore the clinical significance of determining the levels of plasma TXB2,PAgT,6-Keto-PGF1α in the lung carcinoma patients.Methods　The levels of plasma TXB2,PAgT and 6-Keto-PGF1α were determined in 43 patients with lung carcinoma and 45 healthy controls,and 36 cases of 43 patients with lung carcinoma were randomly divided into two groups:(A) conventional treatment plus warfarin sodium,(B) conventional treatment without anticoagulant.We also determined the level of plasma Fib in both group A and group B,besides examined the levels of plasma TXB2,PAgT and 6-Keto-PGF1α before and after treatment.Results　Statistical analysis showed that the levels of TXB2 and PAgT were significantly higher,but the levels of 6-Keto-PGF1α was significantly lower in the patients with lung carcinoma than those in healthy controls(P＜0.05～0.01).The levels of TXB2,PAgT and Fib in group A were significantly lower,but the level of 6-Keto-PGF1α was significantly higher in group A after treatment than before treatment(P＜0.05～0.01).While these four indexes in group B did not significantly change(P＞0.05).Conclusion　The determination of plasma TXB2,PAgT and 6-Keto-PGF1α for lung carcinoma patients are helpful in diagnosis and treatment of lung carcinoma.%目的探讨肺癌患者检测TXB2、PAgT、6-Keto-PGF1α的临床意义。方法检测43例肺癌患者及45例正常人的TXB2、PAgT、6-Keto-PGF1α，并将肺癌组中的36例随机分为华法灵钠治疗组和单纯治疗组。在两组患者治疗前及治疗后，除检测TXB2、PAgT、6-Keto-PGF1α外，附加检测纤维蛋白原(Fib)含量。结果肺癌组的TXB2、PAgT较正常人高，6-Keto-PGF1α较正常人低，差异高度显著(P＜0.01)；华法灵钠治疗后TXB2、PAgT、Fib分别较治疗前明显下降，6-Keto-PGF1α较治疗前上升，差异均具有显著性(P＜0.05～0.01或P＜0.05)，而单纯治疗组上述四项指标均无明显变化(P＞0.05)。结论测定肺癌患者的TXB2、PAgT、6-Keto-PGF1α及Fib含量，对肺癌的诊断及其病情的判定和治疗有一定的参考价值。